Skip to content

EPFL scientists ward off Alzheimer’s

Non classé

18 March 2016

EPFL scientists have developed a subcutaneous cellular implant that can treat Alzheimer’s disease. One of the suspected causes of Alzheimer’s is the over-accumulation of a protein fragment known as beta-amyloid (Abeta) in different areas of the brain. A promising way to remove these abnormal clumps of protein, which are toxic to neurons, is to “tag” […]

EPFL scientists have developed a subcutaneous cellular implant that can treat Alzheimer’s disease.

One of the suspected causes of Alzheimer’s is the over-accumulation of a protein fragment known as beta-amyloid (Abeta) in different areas of the brain. A promising way to remove these abnormal clumps of protein, which are toxic to neurons, is to “tag” them with antibodies that signal the patient’s own immune system to attack and clear them. In order to avoid side effects caused by repeated vaccine injections, the lab of Patrick Aebischer at EPFL has developed an implant that can deliver a steady and safe flow of antibodies to the patient’s brain to clear Abeta proteins.

According to a press release, the device was tested on mice “with great success” over a ten-month period. The mice – a genetic line commonly used to simulate Alzheimer’s disease – showed dramatic reduction of Abeta plaque load. Referred to as “macroencapsulation device”, the implant is easily reproducible for large-scale manufacturing.

Published in the journal Brain, the study demonstrates clearly that encapsulated cell implants can be used successfully and safely to deliver antibodies to treat Alzheimer’s disease and other neurodegenerative disorders that feature defective proteins.